Fennec Pharmaceuticals
FENC
27 hedge funds and large institutions have $40.7M invested in Fennec Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 9 closing their positions.
13% more capital invested
Capital invested by funds: $36M → $40.7M (+$4.77M)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
2.63% less ownership
Funds ownership: 45.17% → 42.54% (-2.6%)
10% less funds holding
Funds holding: 30 → 27 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
Top Sellers
FENC Hedge Fund Activity: Q3 2019 in Review
27 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2019, worth a combined $40.7M — up 13% from $36M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FENC and 6 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Solas Capital Management, adding an estimated $411K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.18M sold.
- 27 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2019, down from 30 in Q2 2019.
- Funds reported $40.7M of Fennec Pharmaceuticals stock for Q3 2019, up 13% quarter-over-quarter.
- 6 funds opened new Fennec Pharmaceuticals positions in Q3 2019 and 9 closed out, a net change of -3 holders.
- The largest Fennec Pharmaceuticals buyer in Q3 2019 was Solas Capital Management, an estimated $411K added.
- The largest Fennec Pharmaceuticals seller in Q3 2019 was Opaleye Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2019.